Abstract
Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have